PRTN3 and rheumatoid arthritis: Therapeutic targetting of the initiation of ACPA responses would therefore be highly desirable, as it could limit or help resolve RA responses, and could be utilised in other diseases in which ACPAs are known to play a role, such as psoriatic arthritis11 and pulmonary tuberculosis12.